Mycophenolate Mofetil Substitution for Cyclosporine A in Renal Transplant Recipients with Chronic Progressive Allograft Dysfunction: The ???Creeping Creatinine??? Study1
- 1 February 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (4) , 466-475
- https://doi.org/10.1097/01.tp.0000151632.21551.00
Abstract
Background. This study determined whether cyclosporine A (CsA)-treated renal allograft recipients with deteriorating renal function (creeping creatinine) secondary to chronic allograft nephropathy (CAN) benefit from the addition of mycophenolate mofetil (MMF) to their immunosuppressive regimen, followed by withdrawal of CsA.Methods. in a controlled, open, multicenter study, CsA-treated renal allograft recipients with progressively deteriorating renal function were randomized to have their CsA discontinued with the concomitant addition of MMF to their regimen (group A) or to continue treatment with CsA (group B). the primary endpoint was the response rate over the 6-month period after withdrawal of CsA in group A or the equivalent time in group B. Response was defined as a stabilization or reduction of serum creatinine (SCr), as evidenced by a flattening or positive slope of the 1/SCr plot and no graft loss. Secondary endpoints included the incidence of acute rejection, graft and patient survival, and changes in selected metabolic parameters.Results. the response rate in the primary intent-to-treat population (n = 122) was 58% (36/62) in group A versus 32% (19/60) in group B (P= 0.0060). the corresponding percentages of responders in the per-protocol population (n = 107) were 60% (36/60) and 26% (12/47), respectively (P=0.0008). There were no acute rejections in group A during the study period. Patients in this group also experienced a significant decrease in total cholesterol.Conclusions. in patients with progressively deteriorating renal function secondary to CAN, addition of MMF followed by withdrawal of CsA results in a significant improvement in transplant function without the risk of acute rejection.Southmead Gen Hosp, Richard Bright Renal Unit, Bristol BS10 5NB, Avon, EnglandUniv Vienna, Sch Med, Dept Nephrol & Dialysis, Clin Internal Med, Vienna, AustriaManchester Royal Infirm, Renal Transplant Unit, Manchester M13 9WL, Lancs, EnglandInternal Clin FNsP, Ostrava, Czech RepublicF Hoffman La Roche Ltd, Div Pharmaceut, Basel, SwitzerlandUniversidade Federal de São Paulo, Hosp Hipertensao & Rim, São Paulo, BrazilUniversidade Federal de São Paulo, Hosp Hipertensao & Rim, São Paulo, BrazilWeb of SciencKeywords
This publication has 23 references indexed in Scilit:
- The Natural History of Chronic Allograft NephropathyNew England Journal of Medicine, 2003
- Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathyKidney International, 2001
- MYCOPHENOLATE MOFETIL, AN ALTERNATIVE TO CYCLOSPORINE A FOR LONG-TERM IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION?1,2Transplantation, 2000
- Chronic allograft nephropathy: An updateKidney International, 1999
- Rethinking Chronic Allograft NephropathyJournal of the American Society of Nephrology, 1999
- LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2Transplantation, 1998
- MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS WITH CYCLOSPORINE-ASSOCIATED NEPHROTOXICITYTransplantation, 1998
- A NOVEL APPROACH TO THE TREATMENT OF CHRONIC ALLOGRAFT NEPHROPATHY1Transplantation, 1997
- CYCLOSPORIN IN THERAPEUTIC DOSES INCREASES RENAL ALLOGRAFT VASCULAR RESISTANCEThe Lancet, 1986
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976